Skip to main content
S&P 5007,743.41+0.51%DOW51,828.62+0.93%NASDAQ27,068.72+0.48%BTC$83,896.00-0.86%ETH$2,687.00-0.12%GOLD$4,320.50+0.52%OIL$92.44-2.29%
Smart Investors Daily
AD

NASDAQ · ADPT

Adaptive Biotechnologies Corporation

Healthcare · Biotechnology

$29.43

Down-$0.14 (-0.47%)

Updated Sep 26, 2026, 7:55 PM

SID Score

6.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.45B
P/E ratio
-41.23
Dividend yield
0.00%
52-week range
$12.00 – $29.96
Volume
1.69M
Avg. volume
2.26M

Price performance

ADPT price history

1M range · 0 trading sessions · Daily adjusted prices

ADPT does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ADPT news

The latest Smart Investors Daily articles mentioning ADPT.

Stock researchCompany · Overview

ADPT research

Overview

Company profile and research snapshot.

Company profile

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$20.33
Implied upside
—
Analysts
14
ADPT recent ratings
DateFirmRatingTarget
Sep 22, 2026BTIGBuy—
Aug 4, 2026Piper SandlerOverweight—
Jul 30, 2026TD CowenBuy—
Jul 30, 2026Morgan StanleyEqual-Weight—
Jul 30, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 17, 2026

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity now preferred SEATTLE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted signifi

Yahoo · Sep 1, 2026

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, September 15, 20

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By